Array/VentiRx Partner On Toll-Like Receptor Drugs In Oncology, Allergy
This article was originally published in The Pink Sheet Daily
Executive SummaryThrough a licensing agreement, VentiRx gains rights to Array’s TLR program containing several development candidates
You may also be interested in...
VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.